Vitality Biopharma

1

• Unlocking the Power of Cannabinoids for Treatment
  of Serious Neurological and Inflammatory
  Conditions

2
Our Mission

• Vitality Biopharma has developed a new class of
  cannabinoid prodrugs, known as cannabosides,
  which upon ingestion can enable the selective
  delivery of THC and cannabidiol (CBD) to the
  gastrointestinal tract.
• Site-specific delivery could enable oral drug
  formulations of cannabinoids to provide
  therapeutic benefits while reducing or avoiding
  the systemic delivery of THC into the
  bloodstream. Currently, high concentrations of
  psychoactive THC in the brain limit the dose of
  cannabinoids that can be used elsewhere in the
  body for treatment of pain and inflammation.

3
Our Technology

• In 2013, we developed a proprietary enzymatic
  biosynthesis production system in order to
  improve the taste of stevia, a natural compound
  used as a high-potency sweetener. This platform
  harnesses a naturally-occurring biological
  process known as glycosylation, which involves
  using enzymes to attach glucose (sugars) to
  small-molecule compounds. Over the last 10 years
  or so, it has become well appreciated within the
  pharmaceutical industry that glycosylation can
  act to generate new natural product libraries
  with improved drug properties. This platform
  technology enables us to readily modify existing
  drug compounds, especially natural products, in
  order to give them attractive new drug properties.

4
Meeting Pharmaceutical Market Demands

• Vitality is developing proprietary cannabinoid
  pharmaceuticals that are compliant with FDA and
  DEA regulations. Oral cannabinoid pharmaceuticals
  are a convenient and desirable option for
  patients and physicians, and they could help
  realize the full therapeutic potential of
  cannabinoid medicines.

5
A Low-Cost, Low-Risk Regulatory Strategy

• Oral prodrugs enable a regulatory strategy with
  lower risk that is akin to specialty
  pharmaceutical development. The company benefits
  from existing clinical studies of cannabinoids
  demonstrating their effectiveness in treating in
  IBD, NBS, MS, neuropathic pain, and additional
  disease indications.

6
Healthcare Life Sciences Expertise

• Senior management is entrepreneurial with a track
  record in healthcare and drug development.
  Laboratory and manufacturing operations are based
  in Northern California, and the RD team includes
  passionate scientists, medical advisers, and
  regulatory affairs specialists.

7
Clinical Trials Unmet Needs

• Clinical Trials Unmet Needs There is increasing
  recognition and acceptance from physicians and
  researchers that there may be vast therapeutic
  potential for cannabinoids, including THC and
  also cannabidiol (CBD), which is not
  mind-altering. This interest has led independent
  research investigators to conduct a wide variety
  of preclinical and clinical studies to examine
  their therapeutic benefits, including for
  treatment of the disease indications.

8
Treatment of Inflammatory Bowel Disease

• Independent clinical trial results suggest that
  cannabinoids will help induce remission in
  Crohns disease patients, even in patients who
  are heavily medicated and have not responded to
  corticosteroids, anti-TNF-alpha drugs (Remicade,
  Humira, etc.), or immunomodulators.

9
About US

• Vitality Biopharma is a cure development company,
  dedicated to unlocking the power of cannabinoids
  to treat serious neurological and inflammatory
  disorders.

10
Contact US
Vitality Biopharma, Inc.

• Address 1901 Avenue of the Stars, 2nd Floor
• City Los Angeles
• State CA
• Zip code 90067
• Country USA
• Phone [phone]
• Email info_at_vitality.bio
• Website http//vitality.bio
• Web Blog http//vitality.bio/investors/news/
• Twitter hhttps//twitter.com/VitalityBio
• Facebook https//www.facebook.com/VitalityBio
• Linkedin.com https//www.linkedin.com/company/vit
  ality-biopharma?trkcompany_logo

11
(No Transcript)